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Background and aims: We aimed at investigating the role of 14q32 microRNAs in intimal hyperplasia and
accelerated atherosclerosis; two major contributors to restenosis. Restenosis occurs regularly in patients
treated for coronary artery disease and peripheral arterial disease. We have previously shown that in-
hibition of 14q32 microRNAs leads to increased post-ischemic neovascularization, and microRNA miR-
494 also decreased atherosclerosis, while increasing plaque stability. We hypothesized that 14q32
microRNA inhibition has beneﬁcial effects on intimal hyperplasia, as well as accelerated atherosclerosis.
Methods: Non-constrictive cuffs were placed around both femoral arteries of C57BL/6J mice to induce
intimal hyperplasia. Accelerated atherosclerotic plaque formation was induced in hypercholesterolemic
ApoE/ mice by placing semi-constrictive collars around both carotid arteries. 14q32 microRNAs miR-
329, miR-494 and miR-495 were inhibited in vivo using Gene Silencing Oligonucleotides (GSOs).
Results: GSO-495 administration led to a 32% reduction of intimal hyperplasia. Moreover, the number of
macrophages in the arterial wall of mice treated with GSO-495 was reduced by 55%. Inhibition of miR-
329 and miR-494 had less profound effects on intimal hyperplasia. GSO-495 administration also
decreased atherosclerotic plaque formation by 52% and plaques of GSO-495 treated animals showed a
more stable phenotype. Finally, cholesterol levels were also decreased in GSO-495 treated animals, via
reduction of the VLDL-fraction.
Conclusions: GSO-495 administration decreased our primary outcomes, namely intimal hyperplasia, and
accelerated atherosclerosis. GSO-495 administration also favourably affected multiple secondary out-
comes, including macrophage inﬂux, plaque stability and total plasma cholesterol levels. We conclude
that 14q32 microRNA miR-495 is a promising target for prevention of restenosis.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).-28, Leiden University Med-
erlands.
).
r Ireland Ltd. This is an open acces1. Introduction
Severe atherosclerosis can cause narrowing and occlusions of
affected arteries that require endovascular intervention (such as
balloon angioplasty with or without stenting) to restore and
maintain blood ﬂow. Unfortunately, vascular damage inﬂicted by
these interventions can lead to rapid restenosis of the artery [1].
Intimal hyperplasia is an important contributor to restenosis,
which is characterized by extracellular matrix rearrangements,s article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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of that, accelerated atherosclerosis is observed, especially under
hypercholesterolemic conditions. Intimal hyperplasia is initiated by
damage to the endothelium caused by vascular interventions and
results in the activation of endothelial cells (ECs). Subsequently,
leukocytes adhere to and inﬁltrate the vessel wall. These leukocytes
secrete inﬂammatory cytokines and chemokines promoting
inﬂammation, and release matrix metalloproteinases and growth
factors leading to extracellular matrix remodelling as well as
smooth muscle cell (SMC) proliferation and migration. Accelerated
atherosclerosis is initiated by severe ﬂow disturbance combined
with the uptake of lipids by macrophages in the vessel wall and
subsequent formation of foam cells under hypercholesterolemic
conditions.
MicroRNAs are short endogenous RNA molecules which,
through binding to the 30UTR of their target mRNA, regulate gene
expression by inhibiting translation of the mRNA into protein. A
single microRNA is able to regulate numerous, up to several hun-
dreds, target genes [2]. The fact that a single microRNA can ﬁne-
tune the expression of large sets of target genes, and thus genetic
programs for speciﬁc physiological processes, makes microRNAs an
interesting therapeutic tool for complex diseases [3].
We have previously shown that several members of a large
microRNA gene cluster on human chromosome 14 (14q32) are
highly involved in vascular remodelling, targeting multiple pro-
cesses important for neovascularization and atherosclerosis [4].
The 14q32 cluster encodes over 54 microRNA genes and is highly
conserved in mammals. Inhibition of 14q32 microRNAs miR-329,
miR-487b, miR-494 and miR-495 improved post-ischemic neo-
vascularization in a hind limb ischemia model [4]. Inhibition of
14q32 microRNA miR-494 also reduced collar-induced plaque size
(accelerated atherosclerosis), increased plaque stability and
decreased plasma cholesterol levels [5]. Han et al. also observed
upregulation of other 14q32 microRNAs (namely miR-431, miR-668
and miR-758) in atherosclerotic aortas of ApoE/ mice compared
to healthy aortas of C57BL/6 mice [6]. Moreover, hypomethylation
of 14q32 microRNAs was observed in human atherosclerotic pla-
ques, resulting in the upregulation of several 14q32 cluster mem-
bers [7]. The role of 14q32 microRNAs in restenosis however, is
unknown.
The involvement of microRNAs in restenosis has been demon-
strated in several studies and was recently reviewed [8]. For
example, inhibition ofmiR-21 decreased neointima formation in rat
carotid arteries after angioplasty, whereas overexpression of miR-
29b inhibited the formation of neointima in balloon-injured rat
carotid arteries [9,10]. Based on our previous ﬁndings, we hypoth-
esized that 14q32 microRNA inhibition would reduce lesion for-
mation in experimental models for restenosis. In this study, we
inhibited 14q32 microRNAs miR-329, miR-494 and miR-495 in a
model for intimal hyperplasia and subsequently, we inhibited miR-
329 and miR-495 in an accelerated atherosclerosis model and
examined the effects on primary outcomes of vascular remodelling
or arterial stenosis. In addition, we studied the effects of 14q32
microRNA inhibition on secondary outcomes such as target gene
regulation, vascular cell proliferation, plaque stability and choles-
terol homeostasis.
2. Materials and methods
2.1. Mice
This study was performed in compliance with the Dutch gov-
ernment guidelines and the Directive 2010/63/EU of the European
Parliament. All animal experiments were approved by the Institu-
tional Committee for Animal Welfare of the Leiden UniversityMedical Center (approval reference numbers 13119 and 12165).
Male C57BL/6J (10 weeks old) animals were purchased from the
Jackson Laboratory. Male ApoE/ (7e14 weeks old at start of diet)
were bred in the local animal breeding facility (Gorlaeus Labora-
tories, Leiden University, Leiden, the Netherlands). C57BL/6J mice
received a chow diet during the whole experiment. ApoE/ mice
were fed aWestern-type diet, containing 0.25% cholesterol and 15%
cacao butter (Special Diet Services) for six weeks, two weeks prior
to surgery. All animals received food and water ad libitum during
the entire experiment. During surgery, mice were anesthetized by
intraperitoneal (i.p) injection of midazolam (8 mg/kg, Roche Di-
agnostics), medetomidine (0.4 mg/kg, Orion) and fentanyl
(0.08 mg/kg, Janssen Pharmaceutica). The adequacy of the anaes-
thesia was monitored by keeping track of the breathing frequency
and the response to toe pinching of the mice. After surgery, mice
were antagonized with a subcutaneous injection of ﬂumenazenil
(0.5 mg/kg; Fresenius Kabi), antesedan (2.5 mg/kg; AST Pharma)
and buprenorphine (0.1 mg/kg; MSD Animal Health).
2.2. Femoral artery cuff mouse model
Intimal hyperplasia was induced by placement of a non-
constrictive cuff around the femoral artery of C57BL/6J mice. The
left and right femoral arteries were isolated and a rigid, non-
constrictive polyethylene cuff was placed around the artery.
Thereafter, the wound was closed by a continuous suture. After 21
days, mice were anesthetized and sacriﬁced via perfusion. Venous
blood was drawn in EDTA collection tubes and centrifuged
(6000 rpm for 10 min at 4 C) to obtain plasma. The thorax was
opened and mild pressure-perfusion (100 mmHg) with PBS was
performed for 4 min by cardiac puncture in the left ventricle. After
perfusion with 3.7% formaldehyde, cuffed femoral arteries were
harvested, ﬁxed 5 h in formaldehyde and parafﬁn-embedded.
2.3. Carotid collar mouse model
Carotid artery plaque formation was induced by perivascular
collar placement as described earlier [11]. In brief, a semi-
constrictive cuff collar was placed around both left and right ca-
rotid arteries to induce accelerated atherosclerosis (n ¼ 15 per
group). Four weeks (28 days) after collar placement, mice were
anesthetized and sacriﬁced via perfusion, after which carotid ar-
teries were harvested, ﬁxed overnight in formaldehyde and
parafﬁn-embedded.
2.4. Gene Silencing Oligonucleotides (GSOs)
Gene Silencing Oligonucleotides (GSOs) were designed with
perfect reverse complementarity to the mature target microRNA
sequences and synthesized by Idera Pharmaceuticals (GSOs kindly
provided by Idera pharmaceuticals). As a negative control, a
scrambled sequence was used, designed not to target any known
murine microRNA. GSOs consist of two single-stranded 20O-
methylated DNA strands, linked together at their 5'ends by a
phosphothioate-linker to avoid TLR-activation [12]. Sequences of
microRNAs and GSOs used are given in Supplemental Table 1.
2.5. Uptake of IRDye-800CW labelled GSOs
Two adult male C57BL/6J mice received one non-constrictive
cuff around the left femoral artery, while the contra-lateral
femoral artery was left unaffected. One day prior to cuff place-
ment, mice were injected intravenously with IRDye-800CW-
labelled GSO-329 (0.4 mg/mouse; Idera Pharmaceuticals) or with
IRDye-800CW-unlabelled control. Mice were sacriﬁced by cervical
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rescence measurements were performed using the FLARE™ NIR
imaging system [13].
2.6. Treatment with GSOs in in vivo models
In case of the femoral artery cuff model, mice received a single
intravenous injection of 1 mg GSO dissolved in 200 ml PBS, one day
before cuff placement. In case of the carotid collar model, mice
received a ﬁrst intravenous injection of 1 mg GSO dissolved in
200 ml PBS, 4 days after collar placement. At day 18 after collar
placement, mice received a second injection of 0.5 mg GSO dis-
solved in 200 ml PBS.
A subset of mice (n ¼ 3 per group for cuff model and n ¼ 6 per
group for collar model) was sacriﬁced 3 days after the ﬁrst GSO
injection in order to establish downregulation of microRNAs in vivo.
2.7. Plasma analysis
Blood was collected from mice prior to surgery, at sacriﬁce and
at indicated timepoints (day 2, day 7, day 21 in cuff model for FACS
analysis), by tail bleeding. The concentration of cholesterol in
plasma was determined by incubation with 0.025 U/ml cholesterol
oxidase (Sigma) and 0.065 U/ml peroxidase and 15 mg/mL choles-
terol esterase (Roche Diagnostics) in polyoxyethylene-9-
laurylether, and 7.5% methanol. Precipath (standardized serum;
Roche Diagnostics) was used as an internal standard. Absorbance
was measured at 490 nm.
For lipid proﬁling, plasmawas pooled (n¼ 5 pooled samples per
group, plasma samples of 3 mice were pooled per sample) and
diluted 6 times, after which fractionation of plasma lipoproteins
was performed using an AKTA-FPLC. Total cholesterol levels were
determined in each fraction and in the original pooled sample using
a colorimetric assay (Roche Diagnostics, kit 11489232). Absorbance
was measured at 490 nm.
2.8. Histology and morphometry
Formaldehyde ﬁxed carotid and femoral arteries were parafﬁn-
embedded and 5 mm thick cross sections of arteries were stained to
visualize vessel morphology. Parafﬁn sections of femoral arteries
were stained with Weigert's Elastin to visualize the elastic laminae
to determine intimal hyperplasia. Parafﬁn sections of carotid ar-
teries were stained with hematoxylin-phloxine-saffron (HPS) to
determine plaque size. Sirius red staining was used to visualize
collagen content.
To visualize macrophages and smooth muscle cells, cross sec-
tions of arteries were re-hydrated and endogenous peroxidase ac-
tivity was blocked. Macrophages and smooth muscle cells were
stained using anti-Mac3 (BD Pharmingen, clone M3/84) and anti-
smooth muscle actin (SMA; DAKO, clone 1A4) respectively and
counterstained using hematoxylin.
To assess proliferation of smooth muscle cells, cross sections ofFig. 1. Expression and inhibition of 14q32 microRNAs miR-329, miR-494 and miR-495, and
(A) Relative expression levels (±SEM) of miR-329, miR-494 and miR-495 in the femoral arter
the aorta (n ¼ 6) and carotid artery of ApoE/ mice (n ¼ 4 pooled samples, 3 carotids were
permission from Wezel et.al. [5]). (B) Mean expression levels, relative to U6, of miR-329, miR
were pooled for 1 sample) are shown here 4 days after GSO treatment (±SEM). *p < 0.05
micrograph the cuffed femoral artery (cuff removed; left) and contra-lateral non-cuffed fem
unlabelled control treated animals and lower panels femoral arteries of IRDye-800CW-labe
Colour images are shown on the left, near-infrared (NIR) images in the middle and an ove
perplasia 21 days after cuff placement in C57BL/6J mice (n ¼ 14e18 per group) treated with
staining of cuffed femoral arteries, dashed line represents lamina elastic interna (scale bar ¼
referred to the web version of this article.)femoral arteries were stained using anti-Ki-67 (proliferation
marker) (Abcam, clone SP6) and anti-SMA (DAKO, clone 1A4). Ki-67
was visualized using Alexa 647 conjugated secondary antibody
(Invitrogen) and SMA was visualized using Alexa 555 conjugated
secondary antibody (Invitrogen). Nuclei were stained using Fluo-
roshield with DAPI (Sigma).
All quantiﬁcations of femoral arteries were performed on six
equally spaced cross sections through the cuffed femoral artery by a
single blinded observer. Vessel wall parameters, collagen content
and smooth muscle cell area were quantiﬁed using Qwin (Leica).
Macrophage content and the number of Ki-67/SMA positive cells in
the cuffed femoral artery of C57Bl6/J mice were counted manually.
Morphometric analysis of carotid arteries was performed on
atherosclerotic lesions at the site of maximal stenosis by a single
blinded observer. Plaque size, necrotic core, collagen content,
smooth muscle cell area and macrophage content were quantiﬁed
using image analysis software for morphometric analysis (Qwin,
Leica).
2.9. Cell culture
Bone marrow (BM) cells isolated from C57BL/6J mice were
cultured for 7 days in RPMI medium supplemented with 20%
inactivated fetal calf serum (FCSi, PAA), 2 mmol/L L-glutamine
(PAA), 100 U/mL penicillin and 100 mg/mL streptomycin and 30%
L929 cell-conditioned medium, as the source of macrophage
colony-stimulating factor (M-CSF), to generate BM-derived mac-
rophages (BMDMs) [14].
Primary cultured murine vascular smooth muscle cells (vSMC)
and cell lines for ﬁbroblasts (3T3) and endothelial cells (H5V) were
cultured in complete DMEM GlutaMAX™ medium (Gibco) sup-
plemented with 10% FCSi, 1% penicillin/streptomycin.
VSMCs, H5V and 3T3 cells were plated in triplicate at a density
of 106 cells/mL. GSOs were added overnight at a concentration of
5 mg/mL, after which the cells were lysed for RNA isolation. For
BMDMs, GSOs were added immediately after isolation from BM in a
concentration of 5 mg/mL. After three days medium was refreshed
with a similar addition of GSOs in a concentration of 5 mg/mL. Four
days later, medium was removed and cells were lysed for RNA
isolation.
2.10. RNA isolation, cDNA synthesis and quantitative PCR (qPCR)
For measuring basal femoral artery microRNA expression three
parafﬁn embedded femoral artery segments from 21 days after cuff
placement were pooled, parafﬁn was removed using xyleen and
tissuewas homogenized by grounding using a Pellet Pestle Cordless
Motor (Kimble Chase Life Science). For analysis of microRNA inhi-
bition three fresh femoral artery segments from 3 days after cuff
placement were pooled and homogenized by grounding using a
Pellet Pestle Cordless Motor (Kimble Chase Life Science). Three
carotid artery segments from 7 days after collar placement (3 days
after GSO injections) were pooled and homogenized using the sameeffects of 14q32 microRNA inhibition on intimal hyperplasia.
y of C57BL/6J mice (n ¼ 3 pooled samples, 3 femoral arteries were pooled for 1 sample),
pooled for 1 sample; data on microRNA expression in ApoE/ mice was adapted with
-494 and miR-495 in cuffed femoral arteries (n ¼ 3 pooled samples, 3 femoral arteries
. (C) Uptake of IRDye-800CW-labelled GSO-329 in the cuffed femoral artery. In each
oral artery (right) are displayed. Upper panels show femoral arteries of IDRye-800CW-
lled GSO-329 treated animals, 24 h after cuff placement and 48 h after GSO-injection.
rlay of colour and NIR images is shown on the right. (D) Quantiﬁcation of intimal hy-
GSOs (±SEM). *p < 0.05 compared to GSO-control. (E) Representative images of elastin
50 mm). (For interpretation of the references to colour in this ﬁgure legend, the reader is
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by grounding with pestle and mortar in liquid nitrogen. Total RNA
was extracted using a standard TRIzol-chloroform extraction
method. RNA concentration and purity were examined by nano-
drop (Nanodrop Technologies). MiR quantiﬁcation was performed
using Taqman® miR assays (Thermo Fisher) following manufac-
turer's protocol. qPCR was performed on the Viia7 system (Thermo
Fisher). Normalization of data was performed using a stably
expressed endogenous control (snRNA U6 and mmu-let-7c).
For in vitro and in vivo experiments, total RNA was extracted
from cells and tissues using the standard TRIzol-choloform
extraction method. RNA was reverse transcribed using high-
capacity RNA to cDNA RT kits (Life technologies) and used for
quantitative analysis of mouse genes with the Viia7 system
(Applied Biosystems). The relative expression of putative miR-495
target genes was quantiﬁed using the QuantiTect SYBR® Green
technology (Qiagen). Normalization of the data was performed by
using stably expressed endogenous controls (Hprt and Rpl27).
Primer sequences can be found in Supplemental Table 2.
2.11. Cholesterol efﬂux assay
BMDMs, cultured and treated with GSOs as described above,
were plated at a density of 0.5  106 cells per well. The following
day, medium was changed with DMEM containing 10% BSA and
1 mCi/mL 3H-cholesterol (loading medium) to which either GSO-
control of GSO-495 was added and cells were treated with
20 mg/mL cholesterol. After 24 h, loading medium was replaced
with DMEM with 10% BSA for 1 h. Next, medium was changed for
control DMEMwith 10% BSA or DMEMwith 10% BSA supplemented
with HDL (50 mg/mL). After 24 h, radioactivity in the cells and
medium was determined by liquid scintillation counting (Packard
1500 Tricard). Cholesterol efﬂux was deﬁned as (dpmmedium/
dpmcells þ dpmmedium) x 100% and shown as the percentage of HDL
speciﬁc efﬂux, corrected for non-speciﬁc efﬂux to control medium.
2.12. Statistical analysis
Data are expressed as mean ± SEM. Comparisons of absolute
miR expression were performed using one-way ANOVA, followed
by a Tukey's multiple comparison test. Comparisons of multiple
treatment groups with the control group were performed using
one-way ANOVA, followed by multiple comparisons without
correction for multiple t-tests. Two-tailed Student's t-tests were
used to compare a single treatment group with the control group. A
level of p < 0.05 was considered signiﬁcant.
3. Results
3.1. In vivo inhibition of miR-329, miR-494 and miR-495 after GSO
treatment in the cuff model
Expression levels of 14q32 microRNAs miR-329, miR-494 and
miR-495 were measured in the femoral arteries of wildtype C57BL/
6J mice and the carotid arteries of ApoE/ mice, representing the
two models used to study post-interventional intimal hyperplasiaFig. 2. Effect of 14q32 microRNA inhibition on vascular smooth muscle cell proliferation an
Quantiﬁcation of intimal (A) and medial (B) smooth muscle cell area (%) 21 days after cuf
Representative images of SMA staining of cuffed femoral arteries (scale bar ¼ 50 mm). Quanti
placement in C57BL/6J mice (n ¼ 16e17 per group) treated with GSO-495 (±SEM). *p < 0.
indicate Ki67/SMA positive cells, dashed lines indicate the elastic laminae (scale bar ¼ 50 m
Quantiﬁcation of intimal (G) and medial (H) macrophage inﬂux (%) 21 days after cuff plac
**p < 0.01 compared to GSO-control. (I) Representative images of Mac3 staining of cuffed fem
ﬁgure legend, the reader is referred to the web version of this article.)and accelerated atherosclerosis. Expression of miR-329, miR-494
andmiR-495was alsomeasured in the aorta of ApoE/mice. In the
femoral arteries of wildtype mice, expression of miR-329 and miR-
495 was highest, followed by miR-494 expression (Fig. 1A, left
panel). As we have previously established, the expression of miR-
495 was highest in the aorta of ApoE/ mice (Fig. 1A, middle
panel), whereas in the carotid arteries of these animals, both miR-
495 and miR-494 were highly expressed (Fig. 1A, right panel) [5].
Next, we measured expression of these microRNAs after GSO
treatment in the femoral cuff model. Expression of miR-329, miR-
494 andmiR-495wasmeasured at a single timepoint in the femoral
artery of in C57BL/6J mice, 3 days after cuff placement, 4 days after
GSO injection. MiR-329 was signiﬁcantly downregulated by 52% in
the femoral arteries of C57BL/6J mice compared to GSO-control
treated animals. MicroRNA inhibition is a time-dependent process
[4] and miR-495 was not downregulated at this speciﬁc timepoint.
Levels appeared reduced by 34% in the femoral arteries of C57BL/6J
mice, but there was no signiﬁcant difference (p ¼ 0.22). For miR-
494, we could not observe downregulation at this speciﬁc time-
point either (Fig. 1B).
3.2. Uptake of GSOs at site of cuff placement
To visualize uptake of GSOs in the femoral artery, C57BL/6J mice
were injected with either IRDye-800CW-labelled GSO-329, or
IRDye-800CW-unlabelled control, one day prior to cuff placement.
As expression of miR-329 was highest in the femoral artery, we
injected mice with IRDye 800CW-labelled GSO-329. Since the GSO
chemistry is comparable for GSO-329, GSO-494 and GSO-495, we
assume similar uptake of the other GSOs. Uptake of labelled GSO-
329 was observed in both cuffed (left) and non-cuffed (right)
femoral arteries, whereas minimal uptake was detected in the
femoral arteries of mice treated with IRDye-800CW control
(Fig. 1C). These data demonstrate effective uptake of GSOs in the
femoral arteries. Previously, we have shown that GSOs are also
taken up speciﬁcally in the carotid arteries of ApoE/ mice, 4 days
and 28 days after collar placement [5].
3.3. Effects of miR-329, miR-494 and miR-495 inhibition on
vascular remodelling in C57BL/6J mice
At 21 days after cuff placement, intimal hyperplasia was
signiﬁcantly reduced by 33% following treatment with GSO-495
compared to GSO-control. Treatment with GSO-329 resulted in a
trend towards decreased intimal hyperplasia by 24% (p ¼ 0.09),
whereas GSO-494 treatment had no effect on intimal hyperplasia
(Fig. 1D and representative images in Fig. 1E). In addition, a
decreased intima/media ratio was observed following GSO-495
treatment (35% reduction). This ratio was not decreased in GSO-
329 and GSO-494 treated animals (Supplemental Fig. 1A). No dif-
ferences were found regarding luminal area and lumenstenosis
following GSO-494 or GSO-495 treatment (Supplemental Fig. 1B
and C). GSO-329 treatment signiﬁcantly increased luminal area
and decreased lumenstenosis in these animals (Supplemental
Fig. 1B and C). These data show a beneﬁcial effect of GSO-495
treatment on intimal hyperplasia in C57BL/6J mice.d macrophage inﬂux.
f placement in C57BL/6J mice (n ¼ 12e13 per group) treated with GSOs (±SEM). (C)
ﬁcation of intimal (D) and medial (E) smooth muscle cell proliferation 21 days after cuff
05. (F) Representative images of Ki67/SMA staining of cuffed femoral arteries, arrows
m). Nuclei are shown in blue, SMA staining in green and Ki67 in red.
ement in C57BL/6J mice (n ¼ 12e13 per group) treated with GSOs (±SEM). *p < 0.05,
oral arteries (scale bar ¼ 50 mm). (For interpretation of the references to colour in this
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wall composition in C57BL/6J mice
To assess the effect of microRNA inhibition on vessel wall
composition following cuff placement, we (immuno-)stained serial
sections with SMA, Mac-3 or Sirius red. No differences were
observed regarding SMC content in the intima and media of GSO
treated groups (Fig. 2A and B, representative images in Fig. 2C).
Since GSO-495 treatment reduced intimal hyperplasia, we exam-
ined the number of proliferating SMCs in this group by staining for
Ki67 and SMA and compared the number of double positive cells
(Ki67þ/SMAþ cells) in GSO-495 treated animals with GSO-control
treated animals (Fig. 2D and E). Inhibition of miR-495 reduced
the number of proliferating SMCs by 47% in the media of these
animals, but not in the intima (Fig. 2D and E, representative images
in Fig. 2F).
Following GSO-494 and GSO-495 treatment, macrophage inﬂux
was signiﬁcantly reduced by 35% and 78% respectively in the
intimal area compared to GSO-control (Fig. 2G). In the medial area
however, macrophage inﬂux was not signiﬁcantly altered following
GSO-494 treatment (p ¼ 0.13) or GSO-495 treatment (p ¼ 0.23)
(Fig. 2H, representative images in Fig. 2I). MicroRNA inhibition did
not alter collagen content in either the intima or the media of GSO
treated animals (Supplemental Fig. 2A and B, representative images
in Supplemental Fig. 2C).3.5. Effects of miR-495 and miR-329 inhibition in the carotid collar
mouse model in ApoE/ mice
Next, we assessed the effects of 14q32 microRNA miR-329 and
miR-495 inhibition on accelerated atherosclerotic plaque forma-
tion. Atherosclerotic plaque sizes were signiﬁcantly decreased with
53% in GSO-495 treated animals (Fig. 3A and representative images
in Fig. 3B). In GSO-329 treated animals, a trend towards a 43%
decrease in atherosclerotic plaque size compared to GSO-control
animals (p ¼ 0.09, Fig. 3A, representative images Fig. 3B) was
observed. In addition to the decreased plaque size, composition of
the lesions was also affected by GSO-495 treatment. Inhibition of
miR-495 resulted in smaller necrotic core sizes (60% reduction),
whereas inhibition of miR-329 had no signiﬁcant effects on necrotic
core size (Fig. 4A). In addition, the percentage of macrophage
content in the lesions was decreased by 30% in GSO-495 treated
animals (Fig. 4B), but not in GSO-329 treated animals. No difference
was observed in the percentage of SMA positive lesion area be-
tween groups (Fig. 4C). Inhibition of miR-495, but not miR-329,
increased collagen content by 139% (Fig. 4D), further increasing
plaque stability.
Plasma cholesterol levels in GSO-495 treated animals were
signiﬁcantly decreased with 13% (Fig. 3C). Lipid proﬁling using
AKTA-FPLC revealed a reduction in the VLDL fraction after treat-
ment with miR-495 inhibition (Fig. 3D). This reduction in plasma
cholesterol and VLDL levels was not observed in animals treated
with GSO-329 (Fig. 3C and D). In order to elucidate the mechanism
behind the VLDL reduction in GSO-495 treated animals, we inves-
tigated the in vitro cholesterol efﬂux in macrophages. We found
that treatment of macrophages with GSO-495 signiﬁcantly
increased cholesterol efﬂux in vitro by 96% (Fig. 3E).Fig. 3. Effect of 14q32 microRNA miR-495 inhibition on plaque size and cholesterol levels.
(A) Quantiﬁcation of plaque size 28 days after collar placement in ApoE/ mice (n ¼ 14e15 p
control. (B) Representative images of HPS staining of carotid arteries (scale bar ¼ 100 mm). (
495, 6 weeks after start of the western type diet. *p < 0.05 compared to GSO-control. (D) Ch
samples of 3 animals were pooled per sample) analysed using AKTA-FPLC. (E) Quantiﬁcati
**p < 0.01.3.6. Target gene regulation after miR-495 inhibition
We investigated the effects of miR-495 inhibition on target gene
regulation. We made a selection of putative target genes that have
predicted binding sites for miR-495 in their 30UTR. Although in vivo
inhibition of miR-495was not statistically signiﬁcant at this speciﬁc
timepoint, we could observe upregulation of miR-495 target genes
Tgfb2 and Il13ra1 in the carotid arteries (Fig. 5B). Furthermore,
there was a trend towards increased expression of target gene
Acvr1 (p ¼ 0.07) in the carotids and target gene Il10 was signiﬁ-
cantly upregulated in the spleen were upregulated in GSO-495
treated animals (p ¼ 0.05) (Fig. 5B). In addition, we determined
the expression of multiple cholesterol metabolism related target
genes of miR-495 in the liver but no differences were observed in
the expression of Lrp6, Mttp, Ldlr and Abca1 (Supplemental Fig. 3).
To investigate the effects of miR-495 inhibition on various in-
dividual cell types in vascular remodelling, H5V endothelial cells,
vSMCs, 3T3 ﬁbroblasts and BMDMs were treated with GSOs against
miR-495. Multiple target genes with predicted binding sites for
miR-495 were examined, including cytokines, complement com-
ponents, lipid-related target genes and tissue inhibitors of metal-
loproteinases (TIMPs). Inhibition of miR-495 led to signiﬁcant
upregulation of Tlr7 in H5V cells and vSMCs (p ¼ 0.05), whereas a
trend towards upregulation of the anti-inﬂammatory Il10 was
observed in 3T3 cells (p ¼ 0.06) and H5V cells (p ¼ 0.11)
(Supplemental Fig. 4). Other genes that showed a trend towards
upregulation after miR-495 inhibition included Cdknb1 (p ¼ 0.09)
in 3T3 cells, Cd59 (p ¼ 0.08) and Ccr2 (p ¼ 0.06) in BMDMs.
4. Discussion
Here, we hypothesized that inhibition of 14q32 microRNAs
would reduce restenosis through decreased intimal hyperplasia
and decreased accelerated atherosclerosis. We show that inhibition
of miR-495 leads to less intimal hyperplasia following vascular
injury and decreased plaque formation in atherosclerosis prone
mice, whilst increasing plaque stability in these animals. In addi-
tion, we investigated the effects of 14q32 microRNA miR-495 in-
hibition on secondary outcomes such as target gene regulation,
smooth muscle cell proliferation, plaque stability and cholesterol
homeostasis. The 14q32 microRNA gene cluster is the largest
knownmammalianmicroRNA gene cluster to date andmany 14q32
microRNAs have been implicated within human disease [15].
Recently, we have reported the role of multiple microRNAs from
this cluster in several aspects of vascular remodelling, including
angiogenesis, arteriogenesis and atherosclerosis [4,5].
MicroRNAs are known for their ability to regulate the expression
of numerous genes [16]. Especially miR-495 may have the ability to
target a large number of genes; bioinformatics analysis using www.
targetscan.org (TargetScan 7.0, consulted January 2016) revealed
over 5103 transcripts with in total 7998 putative binding sites for
human miR-495 (of which 1015 conserved sites and 6983 poorly
conserved sites) and 4879 transcripts with putative binding sites
for murine miR-495 (and a total of 7886 sites). It is therefore un-
likely that the observed effects are attributable to strong regulation
of one target gene in particular, but rather are the sum of modest
regulation of multiple target genes involved in all aspects of the
processes of vascular remodelling studied here, namely intimaler group) treated with GSO-control, GSO-329 or GSO-495. *p < 0.05 compared to GSO-
C) Total cholesterol levels of ApoE/ mice treated with GSO-control, GSO-329 or GSO-
olesterol proﬁle of GSO treated ApoE/ mice (n ¼ 5 pooled samples per group, plasma
on of cholesterol efﬂux (%) from macrophages treated with GSO-control or GSO-495.
Fig. 4. Effects of 14q32 microRNA miR-495 inhibition on lesion composition 28 days after collar placement in ApoE/ mice.
(A) Quantiﬁcation of necrotic core size. (B) Percentage (%) of macrophage inﬂux. (C) Percentage (%) of smooth muscle cell area. (D) Percentage (%) of collagen content. *p < 0.05,
**p < 0.01 compared to GSO-control. Representative images of (A) HPS staining, (B) Mac3 staining, (C) SMA staining and (D) Sirius red staining are shown (n ¼ 13e15 mice per
group, scale bar ¼ 100 mm).
S.M.J. Welten et al. / Atherosclerosis 261 (2017) 26e3634hyperplasia and accelerated atherosclerosis. Moreover, binding of a
certain microRNA to its target gene does not completely silence its
expression, but rather downtunes its expression [2]. This corre-
sponds to the modest effects that we observed on miR-495 target
gene regulation.
In vivo, treatment with GSO-495 led to upregulation of target
genes Tgfb2, Il13ra1 and Il10 and a trend towards upregulation of
Acvr1. IL-13, one of the cytokines secreted by CD4þ Th2-cells, in-
hibits macrophage activation and decreases the production of pro-
inﬂammatory cytokines by activated macrophages [17]. More spe-
ciﬁcally, the IL-13 receptor alpha 1 chain (Il13ra1) is implicated
within the signal transduction route of IL-13 and inhibits inter-
feron-g induced gene expression in macrophages [18]. We didobserved upregulation of Il10 expression speciﬁcally in the spleen
following systemic treatment with GSO-495. Since it has been
shown that splenic-derived IL-10 has anti-inﬂammatory properties
[19,20], it is plausible that the observed increase in splenic Il-10
expression following GSO-495 has a systemic effect on acceler-
ated atherosclerosis. Likewise, IL-10, which is also a Th2 cytokine
has anti-inﬂammatory properties and protects against atheroscle-
rosis and neointima formation by inhibiting macrophage activation
and inhibition of matrix metalloproteinases [21e24]. These ﬁnd-
ings are in line with our results that GSO-495 treatment decreases
macrophage numbers within the arterial lesions investigated. Tgfb2
is known to be an important regulator of collagen synthesis [25].
This is in line with the observed increase in collagen content and
Fig. 5. In vivo expression of miR-495 and putative target genes.
(A) Mean expression levels of miR-495 in carotid arteries, relative to let7c, are shown here 3 days after GSO treatment in ApoE/ mice (n ¼ 4 pooled samples per group, 3 carotids
were pooled per sample). (B) Mean expression levels of putative miR-495 target genes Tgfb2, Il13ra1 and Acvr1 in carotids (n ¼ 5 samples per group; 3 carotids were pooled per
sample), and Il10 in spleen (n ¼ 5 per group), relative to Hprt and Rpl27, are shown here 3 days after GSO treatment in ApoE/ mice. *p < 0.05.
S.M.J. Welten et al. / Atherosclerosis 261 (2017) 26e36 35upregulation of Tgfb2 in the carotid artery. Furthermore, it has been
shown that inhibition of Tgfb1, -b2 and -b3 activity induces
atherosclerosis and favours development of an unstable plaque
phenotype, which suggests Tgfb2 has atheroprotective properties
and could therefore contribute to the reduced plaque formation
seen in this study [26]. Despite the observed upregulation in pu-
tative target genes of miR-495, we cannot rule out the possibility
that the observed upregulation is the result of an indirect effect of
miR-495 inhibition instead of a direct effect of miR-495 inhibition.
Inhibition of miR-495 reduced proliferation of SMCs in neo-
intimal lesions of GSO-495 treated animals. Proliferation and
migration of vascular SMCs is one of the most important events in
intimal hyperplasia [27]. In agreement with the reduced prolifer-
ation of SMCs after miR-495 inhibition, overexpression of miR-495
has previously been shown to increase proliferation of neonatal rat
cardiomyocytes [28]. On the other hand, it has also been shown that
miR-495 promotes proliferation of HUVECs [29]. These and our
ﬁndings demonstrate different actions of microRNAs in different
cell types, which comes with both beneﬁts and limitations for
possible therapeutic uses.
Following GSO-495 treatment, we found a reduction of total
cholesterol levels of 13%, which could mainly be attributed to a
reduction of VLDL. One of the most frequently used therapy against
atherosclerosis is the use of statins, which aims for reduction of (V)
LDL cholesterol levels in the blood. Statins reduce (V)LDL choles-
terol levels in a range of 40e60% depending on the dose adminis-
tered, which subsequently reduces the risk of ischemic heart
disease by 61% and of stroke by 17% [30]. Although we cannot
explain the reduced plaque size and increased stability of the pla-
ques completely by the modest reduction of VLDL plasma choles-
terol levels, it is plausible that this reduction contributes, at least
partly, to the reduced plaque size and increased plaque stability.
This hypothesis is supported by the observed increase in choles-
terol efﬂux from macrophages in vitro following GSO-495treatment. This suggests GSO-495 can inhibit atherogenesis by
facilitating removal of cholesterol from the vessel wall to the liver
in an HDL dependent manner.
Inhibition of miR-495 also led to a decrease in necrotic core size
and macrophage content, while it increased collagen content in
atherosclerotic lesions. A decrease in necrotic core size and
macrophage content together with an increase in collagen content
are characteristics of increased plaque stability [31]. MiR-495 was
thus shown to not only contribute to atherosclerotic lesion for-
mation, but also plaque stability in ApoE/ mice. To our knowl-
edge, we are the ﬁrst to report that inhibition of miR-495 leads to
therapeutic beneﬁts in twomodels of vascular remodelling, namely
the femoral artery cuff model for intimal hyperplasia and the ca-
rotid collar model for accelerated atherosclerosis. Not only were the
lesions in these models reduced in size, but the lesions also con-
tained fewer macrophages and in case of the carotid collar model,
plaque stability was increased. Atherosclerosis is the most common
underlying cause of cardiovascular disease and can lead to,
amongst others, myocardial infarction, ischemic stroke and pe-
ripheral arterial disease. Restenosis occurs upon endovascular in-
terventions performed to target these atherosclerotic lesions and
involves the re-narrowing of arteries. Reducing both intimal hy-
perplasia and accelerated atherosclerosis is of crucial importance
for the prevention of restenosis.
A limitation of this study is the fact that due to the time-
dependent regulation of microRNA expression levels, we cannot
attribute all the observed biological effects to miR-495 down-
regulation with absolute certainty; some of the effects may still be
indirect, rather than direct consequences of GSO-495 administra-
tion. Future studies should therefore include detailed in vivo studies
of time-dependent microRNA downregulation and target gene
upregulation.
Taken together, however, we conclude that GSO-495 adminis-
tration improves both primary and secondary parameters of
S.M.J. Welten et al. / Atherosclerosis 261 (2017) 26e3636restenosis. GSO-495 reduces both intimal hyperplasia and accel-
erated atherosclerosis, which makes miR-495 a highly attractive
therapeutic target for patients treated for occlusive arterial disease
who are at risk of developing restenosis.
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